Ziarco Launches with $27M Series A, Assets from Pfizer
By Nuala Moran
Friday, November 2, 2012
LONDON Four Pfizer Inc. scientists and executives have formed a new company specializing in inflammatory and allergic diseases around assets deemed surplus to requirements following the closure of the U.S. pharma company's UK R&D center in Sandwich, Kent.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.